Codexis, Inc. (CDXS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.430.00%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Codexis aims for $72M to $76M revenue in 2026. It is improving operating income from -$18.95M to -$8.04M. Cash flow from operations is also improving but still negative. Recent earnings beats show some progress.
Codexis is still loss-making with negative cash flow. Revenue growth is slow and uncertain. The company cut 24% of its workforce recently. Operating income remains negative and volatile.
The market expects about 9% revenue growth. Our fair value is near $10.46, reflecting cautious optimism. We see risk in the slow profit and cash flow recovery.
Breaks if: cash flow remains negative below -$10M next year
Improve cash flow from operations to support ongoing operations and investments, including facility build-out.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is intact, supported by recent earnings performance, but the company remains loss-making and faces high risks.
The market appears to have priced in a low expectations gap, suggesting that CDXS is seen as cheap compared to its peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Management is focused on achieving revenue guidance of $72 million to $76 million, but recent results show mixed progress. Operating losses are increasing, though there is some improvement in cash flow from operations, which remains negative.
The long-term thesis hinges on management's ability to meet revenue targets and improve operating income. Additionally, broader sector momentum and economic conditions, such as job growth, will significantly influence CDXS's performance.
The most important moves since the prior daily snapshot.
Company momentum rose by 25.0 points (from 55.0 to 80.0).
Yes, our read has strengthened. The earnings beat supports the growth outlook. Revenue guidance of $72 million to $76 million looks achievable. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Cash used in operations improved from negative $13.1 million in 2026-Q1 to negative $9.6 million in 2026-Q2, showing some progress in cash flow management. The trajectory is delivering modest improvement but cash flow remains negative.
“Cash from operating activities was negative $9.6 million in the second quarter of 2026.”
“Cash from operating activities was negative $13.1 million in the first quarter of 2026.”
Breaks if: operating income worsens or stays below -$8M next year
Focus on reducing operating losses and improving operating income through cost management and revenue growth.
Stated as a priority in 2 of last 2 quarters. Operating loss increased from $8.0 million in 2026-Q1 to $11.2 million in 2026-Q2, indicating limited progress in improving operating income despite management focus. The trajectory shows a worsening operating loss in the recent quarter.
“Loss from operations was $11.2 million for the second quarter of 2026.”
“Loss from operations was $8.0 million for the first quarter of 2026.”
Breaks if: annual revenue falls below $72M in FY26
Deliver full-year 2026 total revenues in the range of $72 million to $76 million as reiterated in multiple quarters.
Stated as a priority in 2 of last 2 quarters. Revenue was $15.2 million in 2026-Q1 and $14.9 million in 2026-Q2, with full-year guidance reiterated at $72 million to $76 million. The trajectory is consistent with management's stated goal, showing stable quarterly revenue but below the midpoint pace, indicating ongoing delivery efforts.
“Codexis reiterated its full-year 2026 financial guidance as follows: Total revenues are expected to be in the range of $72 million to $76 million.”
“Codexis reiterated its full-year 2026 financial guidance as follows: Total revenues are expected to be in the range of $72 million to $76 million.”
In the next 1 to 3 years, CDXS's success will depend on execution against its goals and external market conditions. Not investment advice.